Catabasis Pharmaceuticals Virtual KOL Event 2020

Catabasis Pharmaceuticals Virtual KOL Event 2020

Virtual, September 11, 2020

Please join Catabasis Pharmaceuticals (CATB) for a virtual KOL event at 9AM on Sept 11th to discuss edasalonexent and its potential in patients with DMD.

KOL Speaker:

Craig M. McDonald, M.D.
Professor and Chair
Department Of Physical Medicine & Rehabilitation 
Professor of Pediatrics
Director of Neuromuscular Disease Clinics
Study Chair CINRG Duchenne Natural History Study
University of California Davis

 

General Agenda

Please join Catabasis Pharmaceuticals (CATB) for a virtual KOL event at 9AM on Sept 11th to discuss edasalonexent and its potential in patients with DMD.

KOL Speaker:

Craig M. McDonald, M.D.
Professor and Chair
Department Of Physical Medicine & Rehabilitation 
Professor of Pediatrics
Director of Neuromuscular Disease Clinics
Study Chair CINRG Duchenne Natural History Study
University of California Davis

RSVP for Event / Log Back in

Additional menu options can be found in the menu bar on the left or at the top.

Catabasis Pharmaceuticals Inc [CATB] US$29 MM MCap
Rare dis­ease pipe­line, with lead prod­uct Edasa­lonex­ent in Ph 3 trial in Duchenne mus­cu­lar dys­tro­phy re­gard­less of mu­ta­tion type. North Star Am­bu­la­to­ry As­sess­ment as the pri­mary end­point based on Phase 2 re­sults and FDA in­put. Top-line re­sults ex­pect­ed in 2020. [more in­for­ma­tion]